Praxbind
Chemical Name | idarucizumab |
Dosage Form | Injection (intravenous; 2.5 g/50 mL) |
Drug Class | Monoclonal antibodies |
System | Blood |
Company | Boehringer Ingelheim |
Approval Year | 2015 |
Indication
- For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.